CAR T and Other Emerging Therapies in R/R Multiple Myeloma: Kenneth H. Shain, MD, PhD

Video

The hematologist/oncologist at Moffitt Cancer Center discussed emerging therapies for patients with relapsed/refractory multiple myeloma.

This content originally appeared on our sister site, OncLive.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Subscribe Now!
Recent Videos
Annaiz Grimm, BS, a research scientist at Seattle Children's Research Institute
Prerna Mewawalla, MD, medical director of Apheresis and a hematologist-oncologist in the Division of Hematology and Cellular Therapy at Allegheny Health Network, as well as an associate professor at the Drexel University College of Medicine
Surbhi Sidana, MD, an assistant professor of medicine, bone marrow transplantation, and cellular therapy at Stanford
Related Content
Around the Helix: Cell and Gene Therapy Company Updates – August 27, 2025

Around the Helix: Cell and Gene Therapy Company Updates – August 27, 2025

Noah Stansfield
August 28th 2025
Article
ImmunoLogic Episode 5

ImmunoLogic, Episode 5: "Tumor Infiltrators and Triumphs: The Evolution of TIL Therapy" With Michael T. Lotze, MD

Joseph A. Fraietta, PhD;Michael T. Lotze, MD;Noah Stansfield;Matt Hoffman
August 28th 2025
Podcast
Surbhi Sidana, MD, an associate professor of medicine and associate director for Clinical Research in the Bone Marrow Transplantation and Cell Therapy Division at Stanford University

Cilta-Cel's Efficacy in Second-Line Relapsed/Refractory Multiple Myeloma

Surbhi Sidana, MD;Noah Stansfield
August 28th 2025
Article
ImmunoLogic Episode 4

ImmunoLogic, Episode 4: "Inflammatory Storms and Gentle Balances: Navigating Toxicities in Immunotherapies" With Caroline Diorio, MD, FRCPC, FAAP

Joseph A. Fraietta, PhD;Janna Minehart, MD;Caroline Diorio, MD, FRCPC, FAAP;Noah Stansfield;Matt Hoffman
August 28th 2025
Podcast
Around the Helix: Cell and Gene Therapy Company Updates – August 20, 2025

Around the Helix: Cell and Gene Therapy Company Updates – August 20, 2025

Noah Stansfield
August 28th 2025
Article
Iovance Biotherapeutics’ TIL Therapy Lifileucel Approved for Advanced Melanoma in Canada

Iovance Biotherapeutics’ TIL Therapy Lifileucel Approved for Advanced Melanoma in Canada

Noah Stansfield
August 28th 2025
Article
© 2025 MJH Life Sciences

All rights reserved.